NCT04013672View on ClinicalTrials.gov

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

August 16, 2021

Study Completion Date

February 16, 2022

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Pembrolizumab

200 mg IV every 3 weeks

DRUG

SurVaxM

500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

DRUG

Sargramostim

100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

DRUG

Montanide ISA 51

1 ml per dose dosed every two weeks for 4 doses and then every 3 months

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

David Peereboom

OTHER

NCT04013672 - Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | Biotech Hunter | Biotech Hunter